Ashish Kacholia invests in this healthtech startup

Ace investor Ashish Kacholia has invested Rs 16 crore in CURO Biosciences Private Limited, the parent company of ErlySign, according to a statement today, January 16.

"The funding will be instrumental in finalising clinical trials, securing CDSCO approvals, and bringing ErlySign’s oral cancer detection kit to market. Additionally, it will support research and development, team expansion, and further patent filings," the company said.

ErlySign was founded by Shubhendra Singh and Deovrat Begde with a vision to make early detection of cancer painless, easy, and affordable for everyone. This is India's first-ever salivary biomarker-based test which can identify pre-cancerous conditions much before visible symptoms emerge, revolutionising proactive healthcare and early diagnosis.

ALSO READ: ParkMate receives $1.2 million funding led by growth-stage venture fund Cactus Partners

Commenting on the fundraising, Singh said, “Our initial studies revealed exceptional results, achieving 100% specificity and 98.04% sensitivity. The product, now in the final stages of clinical trials across multiple HCG sites, promises to be a game-changer. Beyond early detection, it will serve as a critical screening tool to eliminate unnecessary biopsies and invasive procedures.”  

ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions within just 15 minutes using a simple, non-invasive saliva sample. This groundbreaking solution addresses the limitations of current diagnostic methods, which are often painful, time-consuming, and expensive. ErlySign's test kit promises a painless, affordable, and immediate alternative for early cancer detection, offering hope for timely intervention and improved survival rates.  

ALSO READ: Foxtale raises $30 million from Japan's KOSE, others